Venturepharm Laboratories Limited, based in Beijing but listed in Hong Kong as a subsidiary of Venturepharm Holdings, has become the largest shareholder of the NASDAQ listed CRO, Commonwealth Biotechnologies Inc. Venturepharm purchased 43.65% of the outstanding common shares of CBI. By completing this sale, Venturepharm follows a pattern in which China-based CROs make deals with complementary companies located in the US. More details...

Stock Symbols: (HKEX: 8225) (NSDQ: CBTE)